Insulet Co. (NASDAQ:PODD) has been assigned a consensus rating of “Buy” from the nineteen research firms that are currently covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $62.73.
A number of brokerages recently commented on PODD. Barclays began coverage on shares of Insulet in a research note on Friday, September 15th. They set an “overweight” rating and a $65.00 price target on the stock. Jefferies Group upped their price target on shares of Insulet from $58.00 to $67.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Canaccord Genuity upgraded shares of Insulet from a “hold” rating to a “buy” rating and upped their price target for the company from $50.00 to $65.00 in a research note on Wednesday, November 1st. Zacks Investment Research cut shares of Insulet from a “buy” rating to a “hold” rating in a research note on Saturday, November 11th. Finally, BidaskClub upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 25th.
Insulet (NASDAQ:PODD) traded down $0.16 on Thursday, reaching $69.49. 553,659 shares of the company’s stock were exchanged, compared to its average volume of 504,102. The company has a debt-to-equity ratio of 4.65, a quick ratio of 4.42 and a current ratio of 4.88. Insulet has a 52-week low of $35.12 and a 52-week high of $72.99.
Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.06. The company had revenue of $121.80 million for the quarter, compared to analysts’ expectations of $114.02 million. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. Insulet’s revenue was up 28.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.05) EPS. research analysts anticipate that Insulet will post -0.42 earnings per share for the current fiscal year.
In other news, Director James C. Mullen bought 2,500 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were acquired at an average price of $67.45 per share, with a total value of $168,625.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 2.60% of the company’s stock.
A number of institutional investors have recently bought and sold shares of PODD. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Insulet by 11.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock worth $118,000 after acquiring an additional 235 shares during the period. SG Americas Securities LLC bought a new stake in Insulet during the 2nd quarter worth approximately $180,000. Wrapmanager Inc. bought a new stake in Insulet during the 2nd quarter worth approximately $217,000. RNC Capital Management LLC bought a new position in shares of Insulet in the 2nd quarter worth $225,000. Finally, Trexquant Investment LP bought a new position in shares of Insulet in the 3rd quarter worth $242,000.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/05/insulet-co-podd-receives-average-rating-of-buy-from-brokerages.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Co. and related companies with MarketBeat.com's FREE daily email newsletter.